Age-Related Macular Degeneration

April sees mixed outcomes in FDA approvals, with promising gene therapies advancing while others face setbacks, highlighting ongoing challenges in ocular treatments.

Clinical evidence may not reflect the incidence of IOI in real-world applications treating age-related macular degeneration and diabetic macular edema.

Analysis suggests that OCT is more consistently accurate and sensitive than color imaging and fluorescein angiography, the accepted standards for imaging.

The FDA identified no issues with the safety or efficacy of aflibercept 8 mg in any of its already approved dosing regimens or indications.

The study indicates which biomarkers should be prioritized to predict neovascular AMD and geographic atrophy.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

Assigned a PDUFA target date of August 27, 2025, the resubmitted application for the wet AMD treatment will offer another chance for US approval.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Aflibercept 8 mg produced the same or better results compared to other anti-VEGFs while requiring fewer injections.

Inflammation due to chronic stress may establish connection between food insecurity and other eye diseases

Cocoa flavanols can be helpful over a brief period, but after 2 years there is little benefit to risk of age-related macular degeneration.

Blood vessel inflammation directly influences incidence of age-related macular degeneration, epiretinal membrane, retinal vascular occlusion, and central serous chorioretinopathy

March highlights groundbreaking advancements in ophthalmology, including FDA approvals for innovative treatments and alarming findings on pediatric eye health post-COVID.

Research presents a correlation between the index and age-related macular degeneration and suggests a causal relationship.

The study proves that cataract, glaucoma, and age-related eye disease can be exacerbated by exposure to several common pollutants simultaneously.

Study finds positive association between weight-adjusted waist index and risk of age-related macular degeneration in adults aged 40 or over.

The pivotal trial investigating sozinibercept combination therapy failed to meet the primary endpoint of mean change in BCVA at 52 weeks.

Veeral Sheth, MD, is joined by the CEO of Oculis to discuss the company's ophthalmic pipeline, including OCS-01 for DME and OCS-05 for acute optic neuritis.

The February 2025 month in review covers 7 key pipeline updates in ophthalmology, including regulatory approvals, label expansions, and topline trial results.

The first of two Phase 3 pivotal trials investigating sozinibercept, COAST completed its final week 52 visit in patients with wet AMD.

Awarded to Luxa Biotechnology, early clinical from the first cohort of patients with dry AMD will be presented at an upcoming medical meeting.

The January 2025 ophthalmology month in review highlights the latest from the FDA, key updates to the ophthalmic pipeline, and the latest episode of New Insight.

Both doses of DURAVYU extended the time to the first supplemental injection versus aflibercept control in the Phase 2 VERONA trial.

With a completed 12-week analysis, Outlook Therapeutics plans to resubmit the Biologics License Application for ONS-5010 in the first quarter of 2025.